Gary Patou

Gary Patou currently serves as Independent Director at Xenon Pharmaceuticals, Inc. since 2004, Chief Medical Officer at Star Therapeutics, Inc. since 2020, and Advisor at Scleroderma Research Foundation since 2021.
Former roles include President & Chief Executive Officer at Cerimon Pharmaceuticals, Inc. from 2008 to 2009; Director at Ligand UK Ltd. in 1995; Senior VP, Director-Project & Portfolio Management at GSK Plc and Smithkline Beecham Pharmaceuticals Ltd. from 1995 to 2000; Director & Chief Medical Officer at Biointervene, Inc.; Chief Medical Officer & Executive Vice President at Oscient Pharmaceuticals Corp.
from 2004 to 2005; President at Genesoft Pharmaceuticals, Inc. in 2004; Chief Medical Officer at Peplin Ltd. in 2007; Chief Medical Officer at Cerimon Pharmaceuticals, Inc. from 2005 to 2006; Senior Medical Advisor at Chiasma, Inc. from 2014 to 2020; Advisor at MPM BioImpact LLC from 2020 to 2022; Chief Medical Officer at Pacira Biosciences, Inc. from 2009 to 2015; Chief Medical Officer at True North Therapeutics, Inc. from 2016 to 2017; and Chief Medical Officer at Blade Therapeutics, Inc. from 2018 to 2020.
Education includes undergraduate, graduate, and doctorate degrees from the University of London.